Physician profile
Matthew G Nessmith
NPI 1265490684
$8,354.44
in general payments reported to CMS, 2019-2025
21 companies · $773 in 2025
The $773 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,117 · 2020: $454 · 2021: $788 · 2022: $1,688 · 2023: $1,135 · 2024: $2,400 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,379 · Travel and Lodging: $928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,379.42 |
| Travel and Lodging | $928.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $2,899.61 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boston Scientific Corporation | $2,024.78 | 2019-2025 | Watchman Flx, Opticross, Watchman Access System |
| Medtronic, INC. | $1,135.53 | 2021-2025 | Corevalve Evolut R, Onyx Frontier, Symplicity G3 |
| Abiomed | $605.72 | 2020-2025 | Impella |
| Cardiovascular Systems INC. | $458.67 | 2020-2023 | Diamondback Coronary |
| Abbott Laboratories | $313.02 | 2020-2023 | Diamondback Coronary, Amplatzer Talisman |
| Janssen Pharmaceuticals, INC | $194.69 | 2019-2020 | |
| Pfizer INC. | $153.89 | 2019-2022 | |
| Medtronic Vascular, INC. | $117.87 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $76.47 | 2019-2022 | |
| Gilead Sciences, INC. | $68.35 | 2019 | |
| Atricure, INC. | $68.11 | 2022-2024 | |
| Biosense Webster, INC. | $51.39 | 2021 | |
| Amarin Pharma, INC. | $46.54 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $40.48 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $21.03 | 2024 | (Bq9) Coronary Ivus |
| Cmp Pharma, INC. | $19.42 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $17.40 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.81 | 2022 | |
| Cook Medical LLC | $14.67 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Nessmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.